10 Best Finch Therapeutics Alternatives & Competitors (2026)

Ferring acquired Rebiotix and markets RBX2660, an approved live biotherapeutic for C. diff. It provides regulated treatment through healthcare systems with defined dosing and safety monitoring. Unlike OpenBiome's foundation model, Ferring uses commercial pricing and distribution. It excels in late-stage clinical data but offers less emphasis on open grant funding or broad research infrastructure.

Vedanta Biosciences advances defined bacterial consortia for C. diff and other indications through clinical trials. It targets precise microbiome modulation with pharmaceutical-grade products. Relative to OpenBiome it prioritizes drug development over direct patient stool banking and operates via investor-funded trials rather than donation-based access programs.

Mayo Clinic runs extensive microbiome research and maintains FMT programs under current regulations. It supplies clinical care, trials, and educational resources for C. diff. Unlike the former OpenBiome model it integrates care within a major hospital system with insurance billing and offers less standalone open-access data repositories.

Microbiome Insights provides sequencing and analysis services for research institutions studying gut health. It supports academic and biotech projects rather than direct patient therapy. In contrast to OpenBiome it functions as a commercial lab service without grant-making or treatment access components.

The AGA funds microbiome research grants and issues clinical guidelines on C. diff and FMT. It emphasizes physician education and policy. Compared to OpenBiome it operates as a professional society with broader GI focus and does not run its own stool bank or direct therapy programs.

Various academic microbiome consortia share data and coordinate studies on C. diff therapies. They continue open-science efforts similar to OpenBiome's past resources. These groups differ by lacking direct treatment delivery and instead concentrate on collaborative publications and standardized protocols across institutions.

Evelo develops oral microbiome medicines targeting inflammatory and infectious conditions including C. diff-related research. It uses monoclonal microbial approaches in clinical trials. Relative to OpenBiome it is a venture-backed drug developer with no foundation-style patient access or donation model.

Second Genome applies microbiome analytics to drug discovery for multiple diseases. It partners with pharma on therapeutic programs rather than providing clinical FMT. Compared with OpenBiome it focuses on computational platforms and commercial partnerships without open patient treatment or grant distribution activities.